GlassScriptPhysician profile
Sarah E Caudill
NPI 1831574094
$1,211.98
in general payments reported to CMS, 2019-2025
18 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.47 · 2022: $363 · 2023: $295 · 2024: $186 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $253.38 | 2023-2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Getinge USA Sales, LLC | $147.83 | 2021-2025 | Cardioroot |
| Abiomed | $119.16 | 2023-2025 | Impella |
| Haemonetics Corporation | $114.26 | 2022 | |
| Zimmer Biomet Holdings, INC. | $103.54 | 2022-2023 | Sternalock Blu System |
| Ethicon US, LLC | $78.61 | 2022 | |
| Edwards Lifesciences Corporation | $64.46 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $60.23 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $54.46 | 2023-2024 | Brilinta, Wainua |
| Biomerieux INC | $42.60 | 2023-2025 | Nephrocheck Liquid Control Kit |
| Alnylam Pharmaceuticals INC. | $30.75 | 2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $30.00 | 2025 | |
| Novo Nordisk INC | $26.68 | 2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $22.57 | 2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $18.08 | 2023 | Assure Wcd |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.06 | 2025 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $15.16 | 2024 | Arcalyst |
| Smith+Nephew, INC. | $14.15 | 2025 | Renasys Touch, "Acticoat 4"" X 4""", Pico |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.